Promising preliminary long-term data for WTX101 in Wilson Disease presented at EASL Annual Meeting
Wilson Therapeutics AB (publ), announced today that preliminary long-term efficacy and safety data from the ongoing extension phase of the company’s Phase 2 trial of WTX101 (bis-choline tetrathiomolybdate), an investigational first-in-class copper-protein-binding agent under investigation as a novel therapy for Wilson Disease, will be presented today during a Late Breaker poster session at The International Liver Congress™ 2018, the Annual Meeting of the European Association for the Study of the Liver (EASL), in Paris. Carl Bjartmar, Chief Medical Officer, Wilson Therapeutics AB